[1] STARK K D C. Epidemiological investigation of the influence of environmental risk factors on respiratory diseases in swine: A literature review. Veterinary Journal, 2000, 159(1): 37-56.
[2] OPRIESSNIG T, GIMENEZ-LIROLA L G, HALBUR P G. Polymicrobial respiratory disease in pigs. Animal Health Research Reviews, 2011, 12(2): 133-148.
[3] AHMAD T A, RAMMAH S S, SHEWEITA S A, HAROUN M, EI-SAYED L H. Development of immunization trials against Pasteurella multocida. Vaccine, 2014, 32(8): 909-917.
[4] GOTTSCHALK M. The challenge of detecting herds sub-clinically infected with Actinobacillus pleuropneumoniae. Veterinary Journal , 2015, 206 (1): 30-38.
[5] MACEDO N, ROVIRA A, TORREMORELL M. Haemophilus parasuis: infection, immunity and enrofloxacin. Veterinary Research, 2015, 46(1): 1-6.
[6] PENG Z, WANG H, LIANG W, CHEN Y, TANG X, CHEN H C, WU B. A capsule/lipopolysaccharide/MLST genotype D/L6/ST11 of Pasteurella multocida is likely to be strongly associated with swine respiratory disease in China. Archives of Microbiology, 2018, 200(1): 107-118.
[7] SCHLUENZEN F, ZARIVACH R, HARMS J, BASHAN A, TOCILJ A, ALBRECHT R, YONATH A, FRANCESCHI F. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature (London), 2001, 413(6858): 814-821.
[8] LEES P C D A. Drug selection and optimization of dosage schedules to minimize antimicrobial resistance. Antimicrobial Resistance in Bacteria of Animal Origin. Washington, DC: ASM Press, 2006: 49-60.
[9] LEI Z, LIU Q, YANG B. The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis. Oncotarget, 2018, 9(2): 1673-1690.
[10] FITTIPALDI N, KLOPFENSTEIN C, GOTTSCHALK M, BROES A, PARADIS M A, DICK C P. Assessment of the efficacy of tilmicosin phosphate to eliminate Actinobacillus pleuropneumoniae from carrier pigs. Canadian Journal of Veterinary Research-Revue Canadienne De Recherche Veterinaire, 2005, 69(2): 146-150.
[11] ROSE M, MENGE M, BOHLAND C, ZSCHIESCHE E, WILHELM C, KILP S, METZ W, ALLAN M, RÖPKE R, NÜRNBERGER M. Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions onin vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae. Journal of Veterinary Pharmacology and Therapeutics, 2013, 36(2): 140-153.
[12] Fda. RE: NADA 141-334, Zuprevo ™ (tildipirosi. n) promotional labeling and advertisements[Z]. 2014.
[13] WATTS J L, SWEENEY M T. Antimicrobial resistance in bovine respiratory disease pathogens: Measures, trends, and impact on efficacy. Veterinary Clinics of North America-Food Animal Practice, 2010, 26(1): 79.
[14] PYÖRÄLÄ S, BAPTISTE K E, CATRY B. Macrolides and lincosamides in cattle and pigs: Use and development of antimicrobial resistance. The Veterinary Journal, 2014, 200(2): 230-239.
[15] GAUTIERBOUCHARDON A V, FERRÉ S, LE G D. Overall decrease in the susceptibility of mycoplasma bovis to antimicrobials over the past 30 years in france. PLoS ONE, 2014, 8: 1-9.
[16] OLSEN A S, WARRASS R, DOUTHWAITE S. Macrolide resistance conferred by rRNA mutations in field isolates of Mannheimia haemolytica and Pasteurella multocida. Journal of Antimicrobial Chemotherapy, 2015, 70 (2): 420.
[17] DIESTE-PÉREZ L, FRAILE L, DE MIGUEL M J, BARBERÁN M, BLASCO J M. Studies on a suitable antibiotic therapy for treating swine brucellosis. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38: 357-364.
[18] BARTRAM D J, MOYAERT H, VANIMISETTI B H. Comparative efficacy of tulathromycin and tildipirosin for the treatment of experimental Mycoplasma bovis infection in calves. Veterinary Medicine and Science, 2016, 2(3): 170-178.
[19] Ema. European public MRL assessment report (EMA/CVMP/709377/ 2009)[Z]. 2010.
[20] Ema. European public MRL assessment report (EMA/CVMP/684147/ 2011)[Z]. 2014.
[21] Ema. Committee for Medicinal Products for Veterinary Use(EMA/ CVMP/709377/2009)[Z]. 2010.
[22] 廖远军. 泰地罗新注射液在猪体内的药代动力学研究[D]. 长春: 吉林大学, 2015.
LIAO Y J. Studies on pharmacokinetics of tildipirosin injection in pigs [D]. Changchun: Jilin University, 2015. (in Chinese)
[23] WANG J, ZHAO T, SUN X, CAO X. Pharmacokinetics of tildipirosin in beagle dogs. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41(1): e49-e52.
[24] MENGE M, ROSE M, BOHLAND C, ZSCHIESCHE E, KILP S, METZ W, ALLAN M, RÖPKE R, NÜRNBERGER M. Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle). Journal of Veterinary Pharmacology and Therapeutics, 2012, 35(6): 550-559.
[25] ANADON A, REEVE-JOHNSON L. Macrolide antibiotics, drug interactions and microsomal enzymes: Implications for veterinary medicine. Research in Veterinary Science, 1999, 66(3): 197-203.
[26] NIGHTINGALE C H. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatric Infectious Disease Journal, 1997, 16(4): 438-443.
[27] COX S R, MCLAUGHLIN C, FIELDER A E. Rapid and prolonged distribution of tulathromycin into lung homogenate and pulmonary epithelial lining fluid of holstein calves following a single subcutaneous administration of 2. 5 mg/kg body weight. International Journal of Applied Research in Veterinary Medicine, 2010, 8(3): 129-137.
[28] GIGUERE S, HUANG R, MALINSKI T J. Disposition of gamithromycin in plasma, pulmonary epithelial lining fluid, bronchoalveolar cells, and lung tissue in cattle. American Journal of Veterinary Research, 2011, 72(3): 326-330.
[29] VENNER M, PETERS J, HOEHENSTEIGER N. Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals. Naunyn- Schmiedebergs Archives of Pharmacology, 2010, 381(2): 161-169.
[30] TORRES F, SANTAMARIA R, JIMENEZ M, MENJÓN R, IBANEZ A. Pharmacokinetics of tildipirosin in pig tonsils. Journal of Veterinary Pharmacology & Therapeutics, 2016, 39(2): 199-201. |